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Metastasis is the major cause of death in cancer
patients, yet the genetic and epigenetic programs
that drive metastasis are poorly understood. Here,
we report an epigenetic reprogramming pathway
that is required for breast cancer metastasis.
Concerted differential DNA methylation is initiated
by the activation of the RON receptor tyrosine kinase
by its ligand, macrophage stimulating protein (MSP).
Through PI3K signaling, RON/MSP promotes exp-
ression of the G:T mismatch-specific thymine glyco-
sylase MBD4. RON/MSP and MBD4-dependent
aberrant DNA methylation results in the misregula-
tion of a specific set of genes. Knockdown of
MBD4 reverses methylation at these specific loci
and blocks metastasis. We also show that the
MBD4 glycosylase catalytic residue is required for
RON/MSP-driven metastasis. Analysis of human
breast cancers revealed that this epigenetic program
is significantly associated with poor clinical out-
come. Furthermore, inhibition of Ron kinase activity
with a pharmacological agent blocks metastasis of
patient-derived breast tumor grafts in vivo.
INTRODUCTION
Metastasis is the main cause of death in cancer patients, and
there are currently no therapies that specifically prevent the met-
astatic process or that can cure metastatic disease. Metastasis
is a multistep, dynamic process for which the mechanisms
remain enigmatic, and a better understanding of specific path-
ways that facilitate and/or sustain metastasis continues to be
required for the development of new treatments. Transcriptional
profiling has clearly demonstrated that there are sets of genes, or
‘‘signatures,’’ expressed in primary tumors that correlate with
metastasis and/or poor survival (van ’t Veer et al., 2002; Minn
et al., 2005; Kang et al., 2003; Bos et al., 2009), although theCmechanisms orchestrating many of these gene expression
programs have not been defined.
The astonishing heterogeneity of tumors (Stephens et al.,
2012) also suggests that tumor cells may achieve metastasis
through many independent pathways, so the likelihood that
targeting a single gene or pathway will prove to be beneficial
for many patients is small. On the other hand, if there are coordi-
nated transcriptional programs that drive a significant proportion
of metastasis, and, if such programs can be identified in tumors
and targeted for therapy, it could advance the field considerably.
It is well established that both genetic and epigenetic events
cooperate at all stages of tumor development and progression
(Baylin and Jones, 2011). One of the most characteristic epige-
netic changes in tumorigenesis is the hypermethylation of CpG
islands in promoters of tumor suppressor genes, which is asso-
ciated with their transcriptional silencing. These methylation
changes involve both histone modifications and chromatin re-
modeling (Suva` et al., 2013).
In addition to epigenetic silencing of specific loci, cancer cell
genomes also simultaneously show global DNA hypomethyla-
tion (Feinberg and Vogelstein, 1983). This phenomenon leads
to abnormal expression of genes and can occur in CpG islands,
shores, and large blocks (Hansen et al., 2011; Bert et al., 2013).
The cause(s) of global DNA hypomethylation is not understood,
nor are the ramifications for tumor progression and metastasis.
Strong evidence has accumulated to support an active DNA
demethylation process that involves enzymatic removal of
5-methylcytosine from DNA (Rai et al., 2010; Cortellino et al.,
2011; He et al., 2011, Andersen and Jones, 2013). There are
several mechanisms now established for active DNA demethyla-
tion, so far all of which involve a DNA repair process, but the
specific signals that activate the DNA demethylation process
remain poorly defined. In particular, how dysfunctional DNA
methylation contributes to tumor metastasis is not understood.
RON, also known as macrophage stimulating 1-receptor
(MST1R), is a member of the Met family of receptor tyrosine
kinases (Ronsin et al., 1993). The biological activity of RON is
mediated by binding of its extracellular ligand, macrophage-
stimulating protein (MSP), also known as hepatocyte growth fac-
tor-like protein (HGFL) and macrophage stimulating 1 (MST1)ell Reports 6, 141–154, January 16, 2014 ª2014 The Authors 141
Figure 1. RON/MSP Signaling Promotes Widespread Metastasis of Human Breast Cancer In Vivo
(A) Immunoblot analysis of RON levels (top) in immortalized mammary epithelial cells (MCF-10A), nonaggressive breast cancer cell lines (MCF7 and T47D),
aggressive breast cancer cell lines (MDA-MB-453, HCC1143, HCC1806), and MCF7 and T47D cells engineered to overexpress RON/MSP. The b-actin (ACTB)
loading control is shown in the bottom panel.
(B) The effect of RON/MSP on spontaneous lung, bone, liver, and brain metastasis of orthotopic MCF7 and T47D tumors. Shown are representative biolumi-
nescent images of primary tumors, lung, bone, liver, and brain metastasis from single mice.
(C) Metastasis frequencies for MCF7 (n = 15), MCF7-RON/MSP (n = 20), T47D (n = 16), and T47D-RON/MSP (n = 14) tumors following orthotopic injection into
mammary fat pad of NOD/SCID mice. All RON/MSP tumors were harvested when size-matched to parental tumors.
See also Figure S1 and Table S1.(Wang et al., 1994; Gaudino et al., 1994). Binding of MSP to its
receptor, RON, activates RON and leads to cellular growth,
motility, and invasion (Wang et al., 1996; Santoro et al., 1996).
Recent studies have documented RON overexpression in a
variety of human cancers including those of the breast, colon,
liver, pancreas, and bladder, which often correlate with poor
outcome (Kretschmann et al., 2010). Moreover, clinical studies
have shown that RON overexpression is associated with metas-
tasis and worse patient outcomes. For example, an analysis of
microarray gene expression data from 295 breast cancer
patients from the Netherlands Cancer Institute (van de Vijver
et al., 2002) revealed that coordinate overexpression of RON,
MSP, and MT-SP1 was associated with significantly shorter
survival when compared with other patients, indicating that
ligand-dependent activation of the RON pathway may promote
tumor progression (Welm et al., 2007). Although RON over-
expression appears to be a feature of many human cancers,
the molecular mechanisms by which RON induces tumorigen-
esis and metastasis are still unclear.
Here, we show that RON/MSP enhances metastasis of
breast cancer xenografts by reprogramming DNA methylation
at specific target genes. RON/MSP-initiated differential-DNA
methylation is the result of PI3K-dependent upregulation of the
methyl-CpG binding domain protein 4 (MBD4), a thymine DNA
glycosylase. Knockdown of MBD4 in RON/MSP-expressing
breast cancer cells reverses the DNA methylation pattern on
specific loci and blocks metastasis. Furthermore, we show that142 Cell Reports 6, 141–154, January 16, 2014 ª2014 The Authorsthe glycosylase catalytic residue of MBD4 is required for its
function in metastasis. We defined a set of genes that are
specifically regulated by RON/MSP through MBD4-directed
aberrant DNA methylation, and determined that the RON/
MBD4 epigenetic pathway is associated with poor prognosis in
breast cancer patients. Importantly, inhibition of Ron signaling
with a small molecule kinase inhibitor blocked metastasis of
patient-derived tumor grafts, indicating that RON inhibitors
may hold promise as antimetastatic agents.
RESULTS
RON/MSP Signaling Promotes Widespread Metastasis
of Human Breast Cancer In Vivo
We examined RON expression in six breast epithelial cell lines,
including immortalized normal mammary epithelial cells, MCF-
10A; two nonmetastatic cancer cell lines, MCF7 and T47D; and
three metastatic cancer cell lines, MDA-MB-453, HCC1143,
and HCC1806 (Figure 1A). RON was overexpressed in meta-
static cancer cell lines compared to normal and nonmetastatic
cancer cell lines. To determine whether RON/MSP drives metas-
tasis, we engineered the nonmetastatic MCF7 and T47D breast
cancer cell lines to stably express firefly luciferase, and infected
them with retroviruses carrying RON and MSP cDNAs (referred
to as MCF7-RON/MSP and T47D-RON/MSP; Figure 1A). Over-
expressing cells had comparable RON levels with the metastatic
breast cancer cell lines.
The effects of RON/MSP gain of function on tumor growth
and/or metastasis of MCF7 and T47D tumors were assessed in
immune-compromised mice by orthotopic implantation into the
cleared inguinal mammary fat pads of 3-week-old female
NOD/SCID mice. The growth of tumors was monitored weekly,
and tumor metastasis was measured by bioluminescence imag-
ing and histology upon necropsy. The MCF7-RON/MSP cells
formed tumors faster compared to parental MCF7 cells, but
this was not the case in the T47D model (Figure S1A). To avoid
confounding effects of tumor size on metastasis, the mice
were euthanized for analysis of metastasis when the tumors
reached the same size endpoint for each group. RON/MSP
expression was sufficient to induce high rates of spontaneous
lung, bone, liver and brain metastasis from MCF7-RON/MSP
and T47D-RON/MSP tumors, compared with little or no metas-
tasis from the parental cell xenografts (Figures 1B and 1C). The
metastases were verified by histological analysis and immuno-
staining for human cytokeratin proteins (Figure S1B). These
results indicated that RON/MSP expression was sufficient to
facilitate the metastatic spread of MCF7 and T47D breast
cancers in vivo to sites that are highly relevant for breast cancer
metastasis. These results are consistent with our previous find-
ings, which showed a significant correlation between RON/
MSP expression and metastasis in patients with breast cancer
(Welm et al., 2007).
To determine the molecular mechanisms by which RON/
MSP drives breast cancer metastasis, we performed RNA
sequencing (RNA-seq) and microarray gene expression
profiling of MCF7 and MCF7-RON/MSP cells. Differentially
expressed genes (DEGs), based on a false discovery rate
threshold of 1% and a fold change of 2, were highly correlated
between the two methods. We identified 220 significant
DEGs in common with both platforms (Table S1). We used
the DAVID bioinformatics database to identify the gene
ontology (GO) terms for the DEGs from RNA-seq and micro-
array and found significant enrichment for genes involved in
plasma membrane, developmental processes, receptor activity
and cell signaling/communication. The GO term analysis
was not used in our subsequent analysis, but indicated that
RON/MSP signaling induces expression of genes whose
functions are consistent with biological pathways relevant to
metastasis. However, the data did not immediately implicate
a clear mechanistic pathway to explain how RON/MSP drives
metastasis.
RON/MSP Signaling Upregulates the Thymine
Glycosylase MBD4 and Drives Altered DNA Methylation
Regulation of DNA methylation is a major mechanism involved
in cell differentiation and neoplastic transformation. The epige-
netic modifications contributing to metastasis, however, are
much less understood. In order to determine whether alterations
in DNA methylation contributed to the selective regulation of
RON/MSP-regulated genes, we performed whole-genome
bisulfite sequencing (WGBS) on MCF7 and MCF7-RON/MSP
cells. We found 1232 differentially-methylated regions (DMRs)
(Figure 2A) that occurred in both gene-body and intergenic re-
gions, both inside and outside CpG islands (Figure 2B). DMRs
regulated by RON/MSP were often intergenic, and there was aCsignificant enrichment of hypomethylated versus hypermethy-
lated regions (Figures 2A–2C).
Next, we wanted to determine to what degree the DEGs
determined by RNA-seq between cell lines were affected by
DNA methylation changes. Eleven percent of the DEGs were
shown to have significant methylation differences between
MCF7 andMCF7-RON/MSP cells. These observations indicated
that RON/MSP expression in MCF7 cells induced massive
changes in DNA methylation, which also affected expression of
particular genes. These data suggested a potential role for
altered DNA methylation in the mechanism of RON/MSP-medi-
ated metastasis.
To assess if the aberrant DNA methylation in RON/MSP cells
was due to differential expression levels or activities of DNA
methyltransferases (DNMTs), we examined mRNA levels of
DNMT3A, DNMT3B and DNMT1 in MCF7 and MCF7-RON/
MSP cells. We found no statistically significant differences (Fig-
ure S2A). We also measured DNMT activity in these cells and
found no significant difference between parental cells and those
expressing RON/MSP (Figure S2B).
The increased representation of hypomethylated versus
hypermethylated DMRs in RON/MSP-expressing cells led us to
consider DNA demethylation as a potential effect of RON/MSP.
Rai et al. (2008) recently discovered amechanism for active DNA
demethylation in zebrafish that involves the cooperative actions
of proteins from the cytidine deaminase family (AID and Apo-
becs), a G:T mismatch-specific glycosylase (Mbd4) and a DNA
repair protein (Gadd45). We examined components of this
DNA demethylase complex in MCF7-RON/MSP and T47D-
RON/MSP cells. We noted robust upregulation of the thymine
DNA glycosylase MBD4 in cells expressing RON/MSP (Fig-
ure 2D). In contrast, another thymine DNA glycosylase (TDG),
which is implicated in a different mechanism of active DNA
demethylation (Cortellino et al., 2011), was not significantly regu-
lated by RON/MSP (Figure 2D). It is also important to note that
the TET family, which mediates DNA hydroxymethylation was
not regulated by RON/MSP (Figure S2C). Upregulation of
MBD4 protein by RON/MSP was validated by western analysis
of protein extracts from MCF7 and T47D cell lines (Figure 2E).
To determine whether RON and MBD4 are coordinately
expressed in actual human breast tumors, we analyzed RON
and MBD4 RNA expression between breast cancer and tumor-
adjacent normal samples in the Cancer Genome Atlas (TCGA)
data set. RON and MBD4 were both upregulated in breast
tumors compared to the normal tissue (Figure 3A). We also
examined RON and MBD4 protein expression in three breast
reduction tissues and 13 human primary breast tumors by west-
ern analysis. RON and MBD4 were highly expressed in all seven
poorly differentiated carcinomas. Lower RON and MBD4 levels
were found in well-differentiated tumor samples, and little to no
MBD4 or RON was detected in control samples taken from
breast reduction tissue (Figure 3B). Together with our data
showing that MBD4 is expressed downstream of RON/MSP in
breast cancer cell lines, these data suggested that RON/MSP
might promote aberrant DNA methylation through the up-
regulation of MBD4. However, the necessity of MBD4 or DNA
methylation for epigenetic regulation of RON/MSP downstream
effectors, and any role in metastasis, had never been described.ell Reports 6, 141–154, January 16, 2014 ª2014 The Authors 143
Figure 2. RON/MSP Signaling Upregulates MBD4 and Drives Aberrant DNA Methylation
(A) Circular representation of genome-wide aberrant DNA methylation caused by RON/MSP expression. Average methylation levels for all of the CGs in 10 Mbp
wide windows are shown in the blue-green tracks (the outermost track shows MCF7 cells; the middle track shows MCF7-RON/MSP cells). The innermost track
indicates the differentially methylated regions (DMRs) between MCF7 and MCF7-RON/MSP cells (false discovery rate >20; differential methylation >0.25). This
diagram for visualization of genome-wide DNA methylation was generated using the Circos software (Krzywinski et al., 2009).
(B) Top, distribution of differentially methylated CpGs on CpG islands (CpGi) shelves (>2–4 kb from island edge) and on CpGi shores (0–2 kb from island edge),
within and outside CpGi. u, upstream of CpGi; d, downstream of CpGi. Bottom, distribution of differentially methylated CpGs across regions of other significance.
TSS 200, within the region 1–200 bp upstream of the TSS; TSS 1500, within the region 201–1,500 bp upstream of the transcription start site (TSS); UTR,
untranslated region; HyperMe, hypermethylated; HypoMe, hypomethylated.
(C) Example of smoothed methylation levels from bisulfite sequencing data for MCF7 (black) and MCF7-RON/MSP (blue) on chromosome 14. A hypomethylation
block is indicated by a red bar.
(D) Real-time quantitative RT-PCR data showing MBD4 and TDG mRNA expression levels, normalized to b-ACTIN mRNA levels, in MCF7, MCF7-RON/MSP,
T47D, and T47D-RON/MSP cells (*p < 0.001).
(E) Western blot with anti-MBD4 showing upregulation of MBD4 protein expression in MCF7-RON/MSP and T47D-RON/MSP cells compared to parental MCF7
and T47D cells (fold change = 5 for MCF7 and fold change = 3 for T47D, p < 0.001, as quantified by ImageJ).
See also Figure S2.Knockdown ofMBD4Blocks RON/MSP-Mediated Breast
Cancer Metastasis
To investigate the possible role of MBD4 downstream of RON/
MSP in breast cancer metastasis in vivo, MCF7-RON/MSP and
T47D-RON/MSP cells were infected with lentiviruses carrying144 Cell Reports 6, 141–154, January 16, 2014 ª2014 The Authorstwo different MBD4-specific small hairpin RNAs (shRNAs)
directed to either the 30 UTR or the coding region
(shMBD4_3UTR and shMBD4_CDS, respectively) or, as con-
trols, anMBD2-specific shRNA (shMBD2) or a scrambled shRNA
(shScr). MBD4 knockdown was validated by western blotting
(Figure 3C). The effect of MBD4 knockdown on spontaneous
metastasis was assessed for both cell lines in NOD/SCID mice.
RON/MSP tumors expressing shMBD4 and shScr from both
cell lines grew similarly to the tumors derived from RON/MSP
cells; therefore, MBD4 loss of function had no effect on primary
tumor growth (Figure S3A). However, spontaneous lung, liver,
bone and brain metastasis was significantly inhibited in animals
carrying MCF7-RON/MSP-shMBD4 and T47D-RON/MSP-
shMBD4 tumors relative to the control tumors expressing
RON/MSP (Figures 3D and 3E). In fact, metastasis frequencies
of RON/MSP-shMBD4 cells were not significantly different
from the original parental cell lines, approaching 0%. The
RON/MSP-shMBD2 and the RON/MSP-shScr control tumors
showed a similar frequency of metastasis as the RON/MSP
tumors (Figures 3D, 3E, S3B, and S3C). To rule out off-target
effects of the MBD4 shRNAs, we generated MBD4 cDNA rescue
constructs (MBD4R-3UTR andMBD4R-CDS) that were resistant
to their respective shRNAs. We then conducted rescue ex-
periments in MCF7-RON/MSP-shMBD4 and T47D-RON/MSP-
shMBD4 cells where re-expression of MBD4was at similar levels
to that found in RON/MSP cells (Figure 3C). Expression of
MBD4R reversed the inhibition of RON/MSP-mediated metas-
tasis by shMBD4 (Figures 3D and 3E). These data confirm that
RON/MSP drives metastasis through upregulation of MBD4, at
least in these two models.
To determine whether MBD4 requires its glycosylase activity
to drive metastasis, we engineered an MBD4 rescue cDNA
containing a single amino acid mutation of the catalytic residue,
D560A. This mutant has previously been shown to be catalyti-
cally dead (Hendrich et al., 1999, Petronzelli et al., 2000). We
transplanted MCF7 and T47D cells expressing RON/MSP-
shMBD4R (D560A) into mammary fad pads of NOD/SCID mice
and monitored metastasis. The mutation prevented the rescue
of the metastasis phenotype observed with the wild-type
MBD4 rescue constructs, suggesting that MBD4 is driving
metastasis through its glycosylase activity (Figures 3D and 3E).
We next sought to determine if MBD4 was also required for re-
programming of DNA methylation downstream of RON/MSP.
Knockdown of MBD4 Reverses Abnormal DNA
Methylation Patterns and Reverses Expression of RON/
MSP-Regulated Genes
To investigate the requirement for MBD4 in aberrant DNA
methylation driven by RON/MSP, we analyzed WGBS data
from MCF7-RON/MSP-shMBD4 compared to MCF7-RON/
MSP. MBD4 knockdown reversed the methylation status of
a specific collection of loci in MCF7-RON/MSP cells. These
regions of aberrant DNA methylation were reprogrammed
following the knockdown of MBD4, to levels that were compara-
ble with parental MCF7 cells (Figures 4A and 4B). It is important
to note that knocking down MBD4 also caused changes in
methylation of some loci that were independent of RON/MSP
(Figure 4C).
To further understand the role of MBD4-mediated aberrant
DNA methylation in gene expression downstream of RON/
MSP, we also performed RNA-sequencing and microarray
gene expression profiling of MCF7-RON/MSP-shMBD4 cells.
We found that a statistically significant 25% of genes that wereCregulated by RON/MSP in MCF7 cells became reversed by
MBD4 knockdown (Figure 4D). Reversal of this gene expression
pattern correlated with lack of metastasis upon MBD4 knock-
down. It is important to note that there were other gene expres-
sion changes induced by RON/MSP that were independent of
MBD4 and vice versa. Thus, as expected, RON signaling does
contribute other changes to cancer cells. Likewise, knockdown
of MBD4 also affected expression of genes other than those
regulated by RON/MSP, suggesting thatMBD4 can also regulate
expression of genes outside of the RON/MSP pathway. To
dissect specific effects of the RON/MSP-MBD4 pathway, we
focused on the gene set that was both RON/MSP-dependent
and MBD4-dependent (reversed in RON/MSP cells when
MBD4 was knocked down).
Using our WGBS and RNaseq data, we identified all of the
genes that were regulated by RON/MSP in MCF7 cells that
were also reversed by MBD4 knockdown. We identified 192
genes (Figure 5A), of which 64 were differentially methylated at
the same locus. Because we could not definitively determine
whether the remaining 128 genes were also regulated by DNA
methylation in a distant region (e.g., enhancer region or inter-
chromosomal interacting regions) (Bert et al., 2013, Hsu et al.,
2013), we grouped all 192 RON/MBD4-dependent DEGs collec-
tively and refer to them as the ‘‘RON/MBD4 epigenetic signa-
ture’’ (Figure 5A).
Specific Subclasses of Human Breast Tumors Possess
the RON/MBD4 Epigenetic Signature, which Correlates
with Poor Prognosis
Although experimentation on human cancer cell lines is essential
for dissection of mechanistic pathways in cancer biology, it is an
extrapolation from bona fide tumors. Therefore, we asked
whether the RON/MBD4 epigenetic reprogramming pathway
that we identified and functionally characterized in cell line
models exists in human breast tumors and, if so, whether it is
associated with survival outcome. To first determine whether
the RON/MBD4 epigenetic signature is present in human breast
tumors, we used a gene module map (Segal et al., 2004) to
examine the expression of 116 genes of the 192 above-
mentioned genes in 997 primary human breast cancers from
the Metabric discovery cohort (the remainder of the genes
were not annotated in the Metabric data set; Curtis et al.,
2012). The RON/MBD4 epigenetic metastasis signature was
present approximately in 25% of the breast cancers (Figure 5B).
Using the published clinical annotations for each tumor (tumor
grade, expression of estrogen and progesterone receptors (ER/
PR), and HER2 status), we found that the RON/MBD4 epigenetic
signature was significantly associated with grade 3, ER, and PR,
tumors (Figure 5B). Several ‘‘intrinsic subtypes’’ of breast cancer
have been previously defined on the basis of more compre-
hensive gene expression profiles: normal-like, luminal type A,
luminal type B, HER2 like, and basal like (Sørlie et al., 2001).
Indeed, the RON/MBD4 epigenetic signature was significantly
enriched in basal-like tumors (Figure 5B).
We next performed Kaplan-Meier analysis examining overall
survival for individuals with breast cancer across the 997 patient
METABRIC data set, using the annotated 116 gene RON/MBD4
epigenetic signature. The expression of these genes wasell Reports 6, 141–154, January 16, 2014 ª2014 The Authors 145
Figure 3. Knockdown of MBD4 Blocks RON/MSP-Mediated Breast Cancer Metastasis
(A) Box plot showing RON and MBD4 mRNA expression in normal breast tissues (white) and breast tumors (dark gray) from The Cancer Genome Atlas (TCGA)
data set.
(B) Western blot for RON and MBD4 proteins in normal human breast tissues from reduction mammoplasties and human primary breast tumor specimens; the
b-actin (ACTB) loading control is also shown.
(C) Successful knockdown of MBD4 expression, shown by western blot on protein lysates from MCF7-RON/MSP-shMBD4 cells (shRNA directed to the 30 UTR
or CDS) and T47D-RON/MSP-shMBD4 cells compared with controls (MCF7-RON/MSP, T47D-RON/MSP, and shRNA scramble control, shScrb). MBD4
(legend continued on next page)
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significantly associated with poor survival (p < 0.05, hazard ratio
[HR] = 1.30, Figure 5C). These data strongly suggest that the
RON/MBD4 pathway exists in a fairly large subset of human
breast cancers (25%), and that detection of the RON/MBD4
epigenetic pathway may significantly contribute to risk assess-
ment in breast cancer patients, even though the signature was
generated a priori from all genes in the RON/MBD4 pathway.
An important corollary to this workwas to next ask howRON reg-
ulates MBD4 and whether the presence of a RON/MBD4 epige-
netic signature would predict response to anti-Ron therapy.
MBD4 Is Upregulated by RON/MSP through PI3K
Signaling
In order to further characterize MBD4 regulation by RON, we
engineered an MCF7-TRE-RON/MSCV-tTA cell line, where
RON expression is under the control of the tetracycline (Tet)
response element (TRE) and is repressed by binding of doxycy-
cline (dox) to the Tet transactivator protein (tTA). As expected, in
the absence of dox the cells expressed RON, which began to be
repressed 4 hr after the addition of dox to the culture medium
and was maximally repressed 48 hr after adding dox (Figure 6A).
Consistent with data in Figures 2D and 2E showing that RON
regulates MBD4, we found that repression of RON also causes
downregulation of MBD4 (Figure 6A). To determine whether
repression of endogenous RON causes downregulation of
MBD4 in other model systems, RON was knocked down using
shRNA via lentiviral infection in both the RON-positive DU4475
breast cancer cell line and in primary culture fromaRON-positive
patient-derived breast tumor graft (DeRose et al., 2011). Scram-
bled shRNAwas used as control. RON knockdown, although not
complete, caused a reduction in MBD4 expression in both
models (Figure 6B). Thus, we concluded that, in all five different
models we examined, RON upregulates MBD4, which can be
reversed with RON downregulation. Therefore, the pathway
has potential to be blocked.
RON is known to transduce a variety of signals that regulate
different downstream pathways, most notably the mitogen-acti-
vated protein kinase (MAPK) and phosphatidylinositol 3-kinase
(PI3K) pathways (Li et al., 1995; Wang et al., 1996). To elucidate
which signaling pathway(s) is required for regulation of MBD4
by RON, we treated the cell lines with varying doses of U0126
(a MEK/ERK inhibitor), or BKM-120 (a PI3K inhibitor) for 0.5 hr
or 1 hr, followed by protein extraction and MBD4 western blot-
ting. Examination of activated (phosphorylated) Erk and PRAS
proteins in each experiment verified that the drugs were effective
in inhibiting their respective targets (Figure 6C). Treatment with
BKM-120, but not U0126, blocked RON/MSP-mediated MBD4
upregulation (Figure 6C). To further validate that MBD4 upregu-re-expression following introduction of rescue cDNA into shMBD4-expressing c
b-ACTIN (ACTB) levels are shown as a loading control.
(D) Top, metastasis frequencies for MCF7 parental tumors (n = 15), MCF7-RON/M
and shScrb (n = 10), sh-MBD4-3UTR (n = 19), or shMBD4-CDS (n = 9). The effects
catalytic mutant shMBD4R [D560A] [n = 9]) are shown at the bottom. Bottom, met
(n = 14), or tumors arising from T47D cells infected with RON/MSP and shScrb (n
constructs (shMBD4R_3UTR [n = 8], shMBD4R_CDS [n = 9], or the catalytic mu
(E) Representative bioluminescent images of lung, bone, liver, and brain metasta
and rescued catalytic mutant on metastasis of various orthotopic MCF7 tumors.
See also Figure S3.
Clation by RON/MSP requires PI3K/Akt signaling, the PI3K p110
alpha catalytic subunit was knocked down in MCF7-RON/MSP
cells by shRNA via lentiviral infection. Knockdown of PI3K
activity was determined using phosphorylation of PRAS as a
surrogate measure (Figure 6D). This experiment showed that
PI3K knockdown led to a reduction in MBD4 expression, similar
to the results with BKM-120 (Figure 6C), demonstrating that
RON/MSP regulates MBD4 through activation of the PI3K
pathway.
To determine whether MBD4 is regulated specifically by RON/
MSP-mediated activation of PI3K, we engineered MCF7 cells
to overexpress the other member of the MET receptor tyrosine
kinase family, MET, which also activated PI3K (Figure S4A).
We found that MET increased MBD4 expression, showing that
MBD4 can be regulated by another, related tyrosine kinase
(Figure S4A). To determine whether any activator of PI3K
signaling could increase MBD4 expression, we treated EGFR-
positive MDA-MB-231 cells with EGF (15 nM) for 30 min, which
was sufficient to activate PI3K as determined by phosphorylation
of AKT (Figure S4B). We observed no upregulation of MBD4,
indicating that MBD4 is not universally regulated by activation
of the PI3K pathway (Figure S4B). It is also important to note
that MBD4 phosphorylation was not altered as a result of
RON/MSP pathway activation (Figure S4C), suggesting that
MBD4 is not a direct target of RON kinase or kinases in the
PI3K pathway.
Treatment with a RON Kinase Inhibitor Prevents
Metastasis of Primary Patient-Derived Tumor Grafts
Ron kinase activity, and its resulting signaling, can be blocked
by small molecule kinase inhibitors. To determine if the RON/
MBD4 pathway can be blocked in patient tumors using RON
kinase inhibitors, and if there is a resulting effect on metastasis,
we utilized four independent experimental systems that are
highly relevant to bona fide breast tumors. First, we chose two
patient-derived tumor grafts (DeRose et al., 2011) that survive
primary culture conditions and treated them with the RON/
MET dual inhibitor OSI-296 (Steinig et al., 2013) in vitro. Inhibition
of RON (verified by reduction of phosphorylated RON protein)
caused downregulation of MBD4 (Figure 7A). Next, we chose
two human tumor graft lines for in vivo studies based on their
RON/MBD4 signature (not shown) and on their relatively fast
growth and robust metastasis (DeRose et al., 2011), which
allows for assessment of tumor growth and metastasis within a
timeline that is practical for drug treatment. The tumor grafts
were implanted orthotopically into cleared mammary fat pads
of NOD/SCIDmice and allowed to grow to 100mm3 before start-
ing treatment with OSI-296. Although there was no significantells (shMBD4R_3UTR and shMBD4R_CDS) is also shown for both cell lines.
SP tumors (n = 20), or tumors arising fromMCF7 cells infected with RON/MSP
of rescue constructs (shMBD4R_3UTR [n = 6], shMBD4R_CDS [n = 14], or the
astasis frequencies for T47D parental tumors (n = 16), T47D-RON/MSP tumors
= 7), sh-MBD4-3UTR (n = 12), or shMBD4-CDS (n = 12). The effects of rescue
tant shMBD4R [D560A] [n = 8]) are shown at the bottom.
sis from single mice illustrate the effects of shScrb, sh-MBD4, rescued MBD4,
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Figure 4. Knockdown of MBD4 Reverses
DNA Aberrant Methylation and Expression
of RON/MSP-Regulated Genes
(A) Representation of smoothed methylation
values from bisulfite sequencing data for MCF7
(black), MCF7-RON/MSP (blue), and MCF7-RON/
MSP-shMBD4 cells (purple) in a representative
region of chromosome 2. The hypomethylation
block in MCF7-RON/MSP that becomes hyper-
methylated by knocking down MBD4 is indicated
by a red bar.
(B) Example of DNAmethylation levels in promoter
regions in MCF7 (black), MCF7-RON/MSP (blue),
and MCF7-RON/MSP-shMBD4 cells (purple). The
hypomethylated block in MCF7-RON/MSP cells
that becomes remethylated by knocking down
MBD4 is indicated by a red bar.
(C) Example of DNA methylation levels in a pro-
moter region that becomes hypermethylated in
shMBD4 cells, independent of RON/MSP expres-
sion (red bar). Bisulfite sequencing data for MCF7
(black), MCF7-RON/MSP (blue), and MCF7-RON/
MSP-shMBD4 cells (purple) are shown. In all
panels, the orange bars indicate CpG islands, and
the black bars show the genes.
(D) Diagrams representing the proportion of exons,
introns, and intergenic regions for which expres-
sion was reversed by knocking down MBD4
(outside shifted circle).effect on tumor growth (data not shown), inhibition of RON in
the in vivo setting caused complete blockade of lymph node (Fig-
ures 7B and 7C) and lung (Figure 7D) metastasis in these two
models.
To determine whether the RON/MBD4 pathway that we previ-
ously defined in MCF7 cells was affected in the tumor grafts
treated with the Ron kinase inhibitor in vivo, we analyzed gene
expression in tumors from mice treated with the vehicle (Trap-148 Cell Reports 6, 141–154, January 16, 2014 ª2014 The Authorspsol) or OSI-296. Indeed, a set of nine
genes (CSGALNACT1, SIGLEC6, SHC4,
ABCA1, PLD1, RNF144A, SLC44A4,
SLC2A13, and AXIN2) from the RON/
MBD4 epigenetic signature was sig-
nificantly deregulated following treat-
ment with the RON inhibitor in vivo.
These data indicated that short-term
inhibition of RON kinase with OSI-296
could not only block metastasis, but
also reverse expression of some genes
within the RON/MBD4 epigenetic metas-
tasis signature.
To assess whether the expression of
these nine RON/MBD4-dependent genes
was associated with patient outcome in
breast cancer cohorts, we performed
Kaplan-Meier analysis examining overall
survival for individuals with breast cancer
across the 997 patient METABRIC data
set (Curtis et al., 2012). The expression
of these nine genes (defined as the subsetof the RON/MBD4 epigenetic signature genes that were
reversed in tumor grafts following RON inhibitor treatment) was
significantly associated with poor survival (p = 0.04, HR = 1.55,
Figure 7E). To validate our findings using additional, independent
data, we generated a meta collection of gene expression data
from an additional 977 patients from five independently pub-
lished studies of breast cancer (van ’t Veer et al., 2002; Miller
et al., 2005; Chin et al., 2006; Desmedt et al., 2007; Heikkinen
Figure 5. Specific Subclasses of Human
Breast Tumors Possess the RON/MBD4
Epigenetic Signature, which Correlates
with Poor Prognosis
(A) Circular representation of the RON/MBD4
epigenetic signature. The outside track represents
the 192 genes regulated by RON/MSP for which
expression was reversed following knockdown of
MBD4 (blue, genes downregulated by RON/MSP
and then reversed by knocking down MBD4 with
shRNA; orange, genes upregulated by RON/MSP
and then reversed by knocking down MBD4). In
larger characters are the genes that are annotated
in the METABRIC data set. The inner track repre-
sents the statistically significant DMRs at these
regions (red, hypermethylated DMRs in MCF7-
RON/MSP and then reversed by knocking down
MBD4; green, hypomethylated DMRs in MCF7-
RON/MSP and then reversed by knocking down
MBD4).
(B) Enrichment pattern of the gene set comprising
the RON/MBD4 epigenetic signature (rows)
across 997 breast tumors (columns). Red and
green indicated a significantly over- or under-
expressed gene, respectively. Are represented
the 582 patients having enrichment or underrep-
resentation of the gene set. Blue bars (right)
indicate individual tumor annotations for breast
cancer subtype. Bottom: association of the RON/
MBD4 epigenetic signature with ER, HER2, and
PR status, as well as intrinsic breast cancer sub-
type, grade, and death (we assigned a p value
according to the hypergeometric distribution).
(C) Kaplan-Meier analysis of overall survival in 997
breast cancer patients from the METABRIC dis-
covery data set (Curtis et al., 2012). Survival curve
of individuals with tumors showing an enrichment
of the 116 annotated genes from the RON/MBD4
epigenetic signature is shown in red; all other
patients are shown in blue (no signature). The
p value indicates a statistically significant survival
difference between these two groups of patients.
The survival hazard ratio was calculated using
univariate Cox’s regression analysis.et al., 2011). The method we utilized to normalize data across
the different data sets was previously described (Segal et al.,
2004; Ben-Porath et al., 2008). Using these data, we confirmed
that the nine gene RON/MBD4 epigenetic signature was signifi-
cantly associated with poor survival (p = 0.008, HR = 1.55,
Figure 7E).
Interestingly, multivariate analysis of the nine gene RON/
MBD4 epigenetic signature revealed that it was not a significant
independent prognostic factor for survival in this data set and
may depict similar risk as ER status (Figure 7F). ER tumors
have a poor prognosis, in part because there are no targeted
therapy options due to lack of defined pathways driving these
tumors. Together, these data highlight the promising potential
for (1) identifying breast cancer patients that might benefit from
a RON inhibitor (approximately 25%); (2) identifying a set of
biomarkers for RON inhibition, and (3) blocking RON to inhibit
breast cancer metastasis.CDISCUSSION
Although more than 90% of cancer mortality is attributable to
metastasis, the requisite events for this complicated process
are still largely unknown. Our ability to treat metastatic disease,
or to better treat those at high risk for metastatic disease in the
adjuvant setting, effectively depends on our ability to block or
reverse the progression of metastases. We have identified an
epigenetic pathway downstream of RON/PI3K signaling that
drives a key metastatic program for breast cancer. Human
breast cancers can be stratified by the presence or absence of
this program, which provides significant prognostic information
for risk of metastatic relapse. Moreover, treatment of mice with
a RON inhibitor blocked metastasis of aggressive patient-
derived tumor grafts. These data provide several important in-
sights, given that a specific event leading to reprogramming of
DNA methylation has not previously been implicated inell Reports 6, 141–154, January 16, 2014 ª2014 The Authors 149
Figure 6. MBD4 Is Regulated by RON/MSP
Signaling through PI3K Pathway
(A) Western blot with anti-RON, anti-MBD4, and
anti-b-ACTIN on protein lysates from the MCF7-
TRE-RON/MSCV-tTA cell line treated with or
without (+/) doxycycline for the indicated times
(duplicate samples).
(B) Western blot showing expression of endoge-
nous RON and MBD4 proteins in the DU-4475
breast cancer cell line and in a patient-derived
breast tumor graft (HCI-014) before and after
infection with lentiviruses carrying RON shRNA
(fold change = 3, p < 0.02, and fold change = 5, p <
0.01, respectively, as quantified by ImageJ).
(C) Top: western blot with anti-MBD4, anti-p-
PRAS,andanti-b-ACTIN inMCF7andMCF7-RON/
MSP cells treated with DMSO or BKM-120 (50 nM,
100 nM, or 500 nM for the time indicated; fold
change = 12, p < 0.001, as quantified by ImageJ).
Bottom: western blot with anti-MBD4, anti-p-ERK,
and anti- b-ACTIN in MCF7 and MCF7-RON/MSP
cells treated with DMSO or U0126 (5 mM, 10 mM, or
50 mM for the time indicated).
(D) Western blot showing the expression of MBD4
and p-PRAS in MCF7 and MCF7-RON/MSP cells
infected with lentiviruses carrying PI3K-p110
shRNA or scrambled shRNA control (fold
change = 2, p < 0.01, as quantified by ImageJ).
See also Figure S4.metastasis and that RON is not known to regulate any aspect
of epigenetic reprogramming.
Our data also indicated that the RON/MBD4 methylation
program may be a prognostic biomarker for patient outcome,
and potentially may be used to predict response to RON
inhibitors. Although the effect on hazard ratio with either sig-
nature (116 or 9 genes) in the large patient cohorts we exam-
ined is somewhat modest, it is consistent with our appreciation
for breast tumor heterogeneity. Outcomes from the TCGA
project in breast cancer revealed very few high-frequency
alterations (Stephens et al., 2012). Therefore, due to intertumor
heterogeneity, small subsets of patients will need to be prese-
lected in order to detect significant therapeutic effects, even
with drugs that are potentially very effective for particular sub-
sets of patients. Our data suggest a way to select populations
of breast cancer patients that might benefit from RON inhibitor
therapy.
Receptor tyrosine kinase signaling has been shown to be
involved in promoting aggressive tumor phenotypes and has
provided a rich source of drug targets (Krause and Van Etten,
2005). Here, we show that RON/MSP functions through
PI3K signaling to induce expression of the DNA glycosylase
MBD4. Once upregulated, MBD4 induces epigenetic reprog-
ramming of breast cancer cells, which drives metastasis in a
glycosylase-dependent manner. Importantly, metastasis can150 Cell Reports 6, 141–154, January 16, 2014 ª2014 The Authorsbe inhibited by MBD4 knockdown, which
reverses the DNA methylation status of a
specific collection of loci in MCF7-RON/
MSP cells. MBD4 knockdown also leads
to reversal in expression of 192 RON/MSP target genes. MBD4 expression can be downregulated
by blocking RON kinase activity or PI3K activity, indicating that
blocking the metastatic program that we have described here
is clinically feasible. PI3K inhibitors are currently in clinical trials
for several cancers, and RON inhibitors are in early stage trials
with multiple compounds in clinical development.
One important issue with regard to RON kinase inhibitors is
that the RON and MET kinase domains are 68% identical.
Most RON-selective, ATP-competitive small molecules inhibit
both RON and MET, and vice versa. However, targeting the
kinase activity of RON is predicted be more effective than the
more specific ligand-blocking antibody approaches because
several different isoforms of RON exist, including ligand-inde-
pendent constitutively active forms (Liu et al., 2011; Wang
et al., 2010). Therefore, the most effective RON inhibitors may
also inhibit MET, at least to some degree. In elucidating the
RON/MBD4 epigenetic reprogramming pathway described
here, we started with a gain-of-function model using RON/
MSP overexpression and then validated the results using a
loss-of-function (RON-specific shRNA) approach, so we are
confident that regulation of MBD4 is truly a function of RON.
Likewise, the RON inhibitors that we used phenocopied the
RON shRNA data, indicating that RON was the effective target.
In the clinical situation, dual inhibition of RON and MET may
actually be beneficial to cancer patients because both proteins
Figure 7. Treatment with aRON Inhibitor, OSI-296, Drastically Decreases Breast CancerMetastasis in Human-Patient-Derived Breast Tumor
Grafts
(A)Western blots with p-RON,MBD4, and b-ACTIN antibodies on protein lysates from primary cultures of the patient-derived tumor graft HCI-007, treatedwithout
() or with 1 mM of the RON inhibitor OSI-296 over the indicated times.
(B) Metastasis frequencies for orthotopically implanted patient-derived tumor grafts HCI-003 and HCI-011 following treatment with OSI-296 (n = 3 and n = 9, for
HCI-003 and HCI-011, respectively) or trappsol (n = 5 for both HCI-003 and HCI-011) vehicle control (p value determined by Fisher’s exact test).
(legend continued on next page)
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can drive aggressive phenotypes (albeit usually in different
cancers), and because MET-selective inhibitors that also inhibit
RON have not shown profound toxicity in clinical trials.
DNA methylation and other epigenetic alterations have been
previously associated with metastasis, especially at the single
gene level (Feng et al., 2010; Chen et al., 2009; Han et al.,
2008). More recently, genome-wide DNA methylation patterns
have been described in breast cancer metastasis (Fang et al.,
2011; Rodenhiser et al., 2008); however, the mechanism(s)
driving altered DNA methylation in metastasis have not been
described. This study shows a specific pathway that drives
epigenetic reprogramming to facilitate metastasis.
Future studies will be required to address how aberrant DNA
methylation is targeted to particular loci in RON/MSP-express-
ing tumors; which aberrant regulated loci (or combinations of
loci) give rise to a metastatic phenotype; and how these
RON/MBD4 target genes promote metastasis. In addition to
the targeted DNA methylation changes at specific loci, factors
such as nuclear organization, chromatin remodeling, and his-
tone modifications may impart profound changes in genome-
wide methylation patterns (Jones, 2012). Thus, aberrant DNA
methylation downstream of RON/MSP may involve a variety
of mechanisms, all of which may serve to promote and/or
sustain metastasis. Just as tumor cells presumably need to
simultaneously regulate cohorts of genes to achieve the com-
plex process of metastasis, clinical treatments to prevent
metastasis may have to inhibit multiple pathways simulta-
neously. Thus, reversing the epigenetic reprogramming events
revealed here may provide a more effective approach to cancer
treatment.EXPERIMENTAL PROCEDURES
In Vivo Metastasis
All animal procedures were reviewed and approved by the University of Utah
Institutional Animal Care and Use Committee. For bioluminescence imaging,
mice were anesthetized and given 150mg/kg of D-luciferin in PBS by i.p. injec-
tion. Five minutes after injection, mice were killed and the organs were ex-
tracted and imaged ex vivo to detect metastasis foci. A detailed description
of analysis is provided in Supplemental Experimental Procedures.
Expression Array Hybridization and Data Analysis
Triplicate biological replicates of hybridization were performed for each cell
line. Differential gene expression was evaluated using the t test (p < 0.01)
and Benjamini and Hochberg correction. The threshold was set at 2-fold
change for both upregulated and downregulated genes. A detailed description
of analysis is provided in Supplemental Experimental Procedures.(C) Sections of axillary lymph nodes isolated from mice carrying orthotopic (inguin
treatment with trappsol or OSI-296. The sectionswere stainedwith H&E (left) or we
to detect human tumor cells.
(D) Sections of lungs isolated from mice carrying orthotopic patient-derived bre
sections were stained with H&E (left) or were immunostained with antibodies spe
(E) Kaplan-Meier analysis of overall survival in 997 breast cancer patients from the
patients from the compendium data set (right, van ’t Veer et al., 2002; Miller et al.
curve of individuals with tumors showing an enrichment of the nine RON/MBD4 e
with OSI-296 compared to the trappsol control is shown in red; all other patients
survival difference between these two groups of patients. The survival hazard ra
(F) Univariate and multivariate cox regression analyses for overall survival in the 9
subtype, and the MBD4/RON signature as variables. HR, hazard ratio.
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Alignments were generated from Illumina Fastq files to the hg19 human
genome with all known and theoretical splice junctions using Novocraft’s
novoalign aligner. A detailed description of analysis is provided in Supple-
mental Experimental Procedures.
Computational Analytical Method for WGBS
The software packages used in this analysis are open source and available
from the USeq (http://useq.sourceforge.net/usageBisSeq.html) project
website (Nix et al., 2010). A detailed description of analysis is provided in
Supplemental Experimental Procedures.
Analysis of Gene-Set Enrichment Patterns
To identify gene-set enrichment patterns, we used methods described
previously (Segal et al., 2004) applied with Genomica. A detailed description
of analysis is provided in Supplemental Experimental Procedures.
Survival Analysis
All survival data were extracted from original publications. p valueswere calcu-
lated using the log rank test comparing the group of individuals with tumors
showing the RON/MBD4 signature to all other individuals. Univariate and
multivariate analyses with Cox proportional-hazards regression were done
on the individual clinical variables.
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